Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Gains from Sales and Divestitures (2023)

60 Degrees Pharmaceuticals (SXTP) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $256000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $256000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $256000.0, a N/A change, with the full-year FY2023 number at $256000.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $256000.0 for Q4 2023 at 60 Degrees Pharmaceuticals.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $256000.0 in Q4 2023 to a low of $256000.0 in Q4 2023.